Prostate Cancer

USPSTF: Final Recommendation Statement on Prostate Cancer Screening

By May 09, 2018

The Task Force recommends that for men 55 to 69 years of age, the decision to undergo prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one.

Erleada Approved for Non-Metastatic, Castration-Resistant Prostate Cancer

By February 15, 2018

Erleada is the first FDA-approved therapy to treat patients with non-metastatic castration-resistant prostate cancer.